Weight-loss drugs didn't curb health costs within two years, data show

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical costs for obese patients increased by 46% to $18,507, with no reduction in obesity-related medical events compared to a control group. These high costs concern employers and government officials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9WsZrNp
via IFTTT